Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 17, 2008, Pages 7956-7967

  Sakami, Satoshi ^a   Kawai, Koji ^a   Maeda, Masayuki ^a   Aoki, Takumi ^a   Fujii, Hideaki ^a   Ohno, Hiroshi ^a   Ito, Tsuyoshi ^a   Saitoh, Akiyoshi ^a   Nakao, Kaoru ^a   Izumimoto, Naoki ^a   Matsuura, Hirotoshi ^a   Endo, Takashi ^a   Ueno, Shinya ^a   Natsume, Kazuto ^a   Nagase, Hiroshi ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Opioid receptor antagonists; Antitussive; Metabolism; Naltrindole

Indexed keywords

17 CYCLOPROPYLMETHY 6,7 DIDEHYDRO 4,5 EPOXY 8' FLUORO 3 METHOXY 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 14 OL METHANESULFONATE; 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 5',6' DIHYDRO 3 METHOXY 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 14 OL METHANESULFONATE; 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 8' FLUORO 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 3,14 DIOL METHANESULFONATE; 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 8' METHOXY 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 3,14 DIOL METHANESULFONATE; 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 9' TRIFLUOROMETHYL 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 3,14 DIOL METHANESULFONATE; 8' BROMO 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 3,14 DIOL METHANESULFONATE; 9' CHLORO 17 CYCLOPROPYLMETHYL 6,7 DIDEHYDRO 4,5 EPOXY 5',6' DIHYDRO 4'H PYRROLO[3,2,1 IJ]QUINOLINO[2',1':6,7]MORPHINAN 3,14 DIOL METHANESULFONATE; ANTITUSSIVE AGENT; DELTA OPIATE RECEPTOR ANTAGONIST; TRK 851; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITUSSIVE AGENTS; CAPSAICIN; COUGH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR CONFORMATION; NALTREXONE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 50349103026     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.07.065     Document Type: Article

References (35)

1. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., and Uhl G.R. FEBS Lett. 338 (1994) 217
2. Mansson E., Bare L., and Yang D. Biochem. Biophys. Res. Comm. 202 (1994) 1431
3. Knapp R.J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G., Varga E.V., Hruby V.J., Roeske W.R., and Yamamura H. Life Sci. 54 (1994) L463
4. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., and Endo T. Chem. Pharm. Bull. 46 (1998) 366
5. Nagase H., Kawai K., Hayakawa J., Wakita H., Mizusuna A., Matsuura H., Tajima C., Takezawa Y., and Endoh T. Chem. Pharm. Bull. 46 (1998) 1695
6. Fujii H., Narita M., Mizoguchi H., Hirokawa J., Kawai K., Tanaka T., Tseng L.F., and Nagase H. Bioorg. Med. Chem. Lett. 14 (2004) 4241
7. Eddy N.B., Friebel H., Hahn K., and Hennies H. Bull. WHO 40 (1969) 425
8. Karlsson J.A., Lanner A.S., and Persson C.G.J. Pharmacol. Exp. Ther. 252 (1990) 863
9. Kamei J., Tanihara H., and Kasuya Y. Eur. J. Pharmacol. 187 (1990) 281
10. Kamei J., Tanihara H., and Kasuya Y. Eur. J. Pharmacol. 203 (1991) 153
11. Kamei J., Tanihara H., and Kasuya Y. Res. Commun. Chem. Pathol. Pharmacol. 76 (1992) 375
12. Portoghese P.S., Sultana M., Nagase H., and Takemori A.E.J. Med. Chem. 31 (1988) 281
13. Portoghese P.S., Sultana M., and Takemori A.E.J. Med. Chem. 33 (1990) 1714
14. Takemori A.E., Sultana M., Nagase H., and Portoghese P.S. Life Sci. 50 (1992) 1491
15. Kamei J., Iwamoto Y., Suzuki T., Misawa M., Nagase H., and Kasuya Y. Eur. J. Pharmacol. 249 (1993) 161
16. Kamei J. Pulm. Pharmacol. Ther. 15 (2002) 235
17. Ombardo F., Blake J.F., and Curatolo W.J.J. Med. Chem. 39 (1996) 4750
18. Abraham M.H., Chada S., and Mitchell R.J. Pharm. Sci. 83 (1994) 1257
19. Hitchcock S.A., and Pennington L.D.J. Med. Chem. 49 (2006) 7559
20. Sakami, S.; Maeda, M.; Kawai, K.; Aoki, T.; Kawamura, K.; Fujii, H.; Hasebe, K.; Nakajima, M.; Endo, T.; Ueno, S.; Kamei, J.; Nagase, H. J. Med. Chem. in press.
21. As a parameter of hydrophobicity, Clog P values of compounds were calculated using ChemDraw Ultra 9.0 (CambridgeSoft Corporation). The Clog P values of selected compounds are as follows: NTI, 3.22; 1a, 4.20; 1b 4.78; 1c, 4.37; 1q, 4.96; 1u, 5.11; 1p, 5.68.
22. Lötsch J. J. Pain Sympt. Manage 29 (2005) 10
23. Rosenblum S.B., Huynh T., Afonso A., Davis Jr. H.R., Yumibe N., Clader J.W., and Burnett D.A. J. Med. Chem. 41 (1998) 973
24. Manoury P.M., Binet J.L., Rousseau J., Lefevre-Borg F.M., and Cavero I.G.J. Med. Chem. 30 (1987) 1003
25. Peglion J.-L., Goument B., Despaux N., Charlot V., Giraud H., Nisole C., Newman-Tancredi A., Dekeyne A., Bertrand M., Genissel P., and Millan M.J.J. Med. Chem. 45 (2002) 165
26. Sasatani S., Miyazaki T., Maruoka K., and Yamamoto H. Tetrahedron Lett. 43 (1983) 4711
27. Nystrom R.F., and Berger C.R.A.J. Am. Chem. Soc. 80 (1958) 2896
28. Ramsay T.W., Slater G.R., and Smith P. Synth. Commun. 25 (1995) 4029
29. Hughes J., Kosterlitz H.W., and Leslie F.M. Br. J. Pharmacol. 53 (1975) 371
30. Berrier C., Jacquesy J.C., Jouannetaud M.P., and Renoux A. New J. Chem. 11 (1987) 605
31. Fujita K., Yamamoto K., and Yamaguchi R. Org. Lett. 4 (2002) 2691
32. Murahashi S., Imada Y., and Hirai Y. Bull. Chem. Soc. Jpn. 62 (1989) 2968
33. Mash E.A., and Aavula B.R. Synth. Commun. 30 (2000) 367
34. Forsberg K., and Karlsson J.A. Acta Physiol. Scand. 128 (1986) 319
35. Schild H.O. Br. J. Pharmacol. Chemother. 4 (1949) 242